Chapter 25. Antibodies as Drug Carriers and Toxicity Reversal Agents

作者: Saul B. Kadin , Ivan G. Otterness

DOI: 10.1016/S0065-7743(08)60386-3

关键词: MonoclonalChlorambucilDrug carrierRadioimmunoassayProtein purificationBiologyCytotoxic T cellToxicityPharmacologyAntibody

摘要: Publisher Summary This chapter focuses on the application of tumor specific antibodies in transporting therapeutic agents to precise target sites and anti-drug intoxicity reversal. In addition their other uses, have been used numerous diagnostic analytic operations. Antibodies carry drugs, toxins, enzymes, radioactivity, boron tissue sites, particularly treatment cancer, where employment such regimens is governed by severe constraints that arise from generally cytotoxic nature. efforts maximize ratios those previously demonstrated promising anti-tumor activities as single agents, drug-antibody complexes received major share attention. The most extensively studied complex derived chlorambucil, cytotoxic, alkylating agent reacts with biologically important nucleophiles. report enzymes could be coupled resultant retention both immunologic enzymatic was instrumental development enzyme–antibody, conjugates designed demonstrate activities. radioimmunoassay method has led routine elicitation drugs. systematic utilization reverse effects drugs more recent occurrence. Recent advent monoclonal hybridoma technique made production pure, monospecific high titer possible will a profound impact future research this area. modern protein purification techniques, use non-complement fixing, relatively non-immunogenic, rapidly excreted fab antibody fragment, establishment viable for reversing toxicity

参考文章(96)
R. F. Clutton, C. R. Harington, M. E. Yuill, Studies in synthetic immunochemistry Biochemical Journal. ,vol. 32, pp. 1119- 1132 ,(1938) , 10.1042/BJ0321119
Tumor-localizing antibodies purified from antisera against Murphy rat lymphosarcoma. Journal of the National Cancer Institute. ,vol. 17, pp. 517- 532 ,(1956) , 10.1093/JNCI/17.4.517
Alonza Johnson, David Pressman, Eugene D. Day, The Effect of Iodination on Antibody Activity Journal of Immunology. ,vol. 84, pp. 213- 220 ,(1960)
Charles W. Parker, Gordon W. Philpott, Eileen H. Grass, Affinity cytotoxicity with an alcohol dehydrogenase-antibody conjugate and allyl alcohol. Cancer Research. ,vol. 39, pp. 2084- 2089 ,(1979)
T. Ghose, A. Guclu, J. Tai, A. S. Macdonald, S. T. Norvell, J. Aquino, Antibody as carrier of131I in cancer diagnosis and treatment Cancer. ,vol. 36, pp. 1646- 1657 ,(1975) , 10.1002/1097-0142(197511)36:5<1646::AID-CNCR2820360518>3.0.CO;2-A
Meir Wilchek, Ruth Arnon, Ruth Maron, Michael Sela, Esther Hurwitz, Ronald Levy, The Covalent Binding of Daunomycin and Adriamycin to Antibodies, with Retention of Both Drug and Antibody Activities Cancer Research. ,vol. 35, pp. 1175- 1181 ,(1975)
D A L Davies, S Buckham, A J Manstone, Protection of mice against syngeneic lymphomata: II. Collaboration between drugs and antibodies. British Journal of Cancer. ,vol. 30, pp. 305- 311 ,(1974) , 10.1038/BJC.1974.197
Charles W. Parker, William T. Shearer, Richard J. Bower, Gordon W. Philpott, Selective Cytotoxicity of Hapten-Substituted Cells with an Antibody-Enzyme Conjugate Journal of Immunology. ,vol. 111, pp. 921- 929 ,(1973)